Drug profile · INN
eltrombopag
REVOLADE
eltrombopag (REVOLADE) is a thrombopoietin receptor agonist. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — eltrombopag
- US status
- approved
- Class
- Blood and blood forming organs (B02)
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
eltrombopag (REVOLADE) is a thrombopoietin receptor agonist. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombopoietin receptor agonist
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eltrombopag?
eltrombopag (REVOLADE) is a thrombopoietin receptor agonist. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for eltrombopag?
REVOLADE is a marketed brand name for eltrombopag. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eltrombopag?
eltrombopag has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.